Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01604941 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy
A Phase 2 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01604941 is a Phase 2 study that was terminated before completion, run by Shire. The registered enrollment target is 32 participants.
The verdict
NCT01604941, a Phase 2 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate SSP-004184AQ in patients with transfusional iron overload whose primary diagnosis is hereditary or congenital anemia. SSP-004184AQ is an iron chelator under development for chronic daily oral administration to patients with transfusional iron overload.
Interventions
- DRUG SPD602
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-09-14 |
| Est. Completion | 2014-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01604941
The ClinicalTrials.gov registry entry for NCT01604941 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPD602 is the first listed.
NCT01604941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01604941 about?
NCT01604941 is a clinical study titled "Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy". The purpose of this study is to evaluate SSP-004184AQ in patients with transfusional iron overload whose primary diagnosis is hereditary or congenital anemia. SSP-004184AQ is an iron chelator under development for chronic daily oral administration to patients with transfusional iron overload.
What is the current status of trial NCT01604941?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2012-09-14. Estimated completion is 2014-04-18.
What interventions are being tested in trial NCT01604941?
The interventions under investigation include: SPD602 (DRUG).
Who is sponsoring clinical trial NCT01604941?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.